Q&A with Steve Strickland, Sensient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Steve Strickland, Sensient
Steve Strickland, general manager of Sensient Pharmaceutical Coating Systems, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 7, pp. 84

Q&A with Steve Strickland, general manager of Sensient Pharmaceutical Coating Systems

PharmTech:



What is the biggest industry challenge you're now facing?

Strickland:

A major challenge is maintaining continuous scientific innovation to meet the product demands of our customers. We are constantly looking for opportunities to expand our technical expertise and service either through internal development or acquisition.

I think that the consolidation within the pharmaceutical industry we serve will continue to play a role in our growth. Consolidation often brings personnel change, accompanied by shifts in the direction of research and development. We need to evolve along with our customers based on their changing needs.

PharmTech:

How do you stay abreast of new developments in the industry?

Strickland:

Our primary method of staying on top of industry developments is listening to our customers. Also, trade shows and trade publications are an excellent source of emerging industry trends, and we'll continue to rely on them.

PharmTech:

Do you see a new industry trend emerging?

Strickland:

Yes, the trend toward globalization of our industry continues to gain momentum. For example, the emergence of global markets, the multinational presence of pharmaceutical companies, and the location of manufacturing sites around the world demand an increased knowledge of the accompanying regulatory requirements.

PharmTech:

What is the most common demand your clients are currently making of you?

Strickland:

They demand high product quality. In an industry that is constantly under scrutiny, our customers demand excellence in the quality and performance of our products.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here